Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a ...
Given CEO Gavin MacLaren is banking $7 million a year to make Corrs a top-tier firm, these are the sorts of clients he ...
(Reuters) -An Australian court on Wednesday stopped U.S. drugmaker Cosette from abandoning its A$672 million ($437.6 million) takeover of Mayne Pharma, which now awaits clearance from the Foreign ...
With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading force in women’s healthcare. The New Jersey-based drugmaker agreed to ...
Cosette Pharmaceuticals Inc., a Bridgewater company that focuses on women’s health and cardiovascular medicines, announced June 8 it completed the acquisition of the global rights to Intrarosa from ...
Bridgewater-based Cosette Pharmaceuticals announced Feb. 20 it entered into an agreement to acquire Mayne Pharma Group Ltd. in a $430 million deal. Mayne is an Australian-headquartered specialty ...
Apurva Saraf, President and CEO of Cosette Pharma, stated, "This is a pivotal product approval, and a testament to our unwavering dedication to R&D, operational excellence and innovation. This is ...
In this critical role, Jeff will lead Cosette’s best-in-class quality and regulatory affairs organizations, maintaining the company’s rigorous quality standards and further establishing Cosette’s ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--#RandD--Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications ...
Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results